Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211503 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL1009942 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL9875114 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL7784378 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL27274855 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL18585071 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL5561948 | 1.00 | L3MBTL1 (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL713499 | 0.98 | TSHR (0.50) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL6263416 | 0.93 | TSHR (0.52) | L3MBTL1TDP1TSHREPHX2TEAD3 | |
| SCHEMBL710282 | 0.93 | TSHR (0.52) | L3MBTL1TDP1TSHREPHX2TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739652-A1 | LIPIDS AND COMPOSITIONS THEREOF | Kernal Biologics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4727915-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025010290-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| CN-119264001-A | Nitrogen-containing chain compound, preparation method, composition containing nitrogen-containing chain compound and application of nitrogen-containing chain compound | 上海蓝鹊生物医药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240423914-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2024-12-26 | — | — | US | disclosed |
| WO-2024259315-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2024-12-19 | — | — | WO | disclosed |
| EP-4433464-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | Astrazeneca AB (SE) | 2024-09-25 | — | — | EP | disclosed |
| CN-118234713-A | Novel lipids for delivery of nucleic acid segments | 阿斯利康(瑞典)有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-06-15 | — | — | US | disclosed |
| US-20040253177-A1 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | GENERAL HOSPITAL CORPORATION, THE | 2004-12-16 | — | — | US | disclosed |
| WO-2004093650-A2 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-5656260-A | CONSISTS OF (3Z,,6Z)DODECADIENE-12-OLIDE AND 13-METHYL-(3Z,5Z)-13-OLIDE TOGETHER WITH FUNGAL VOLATILE SELECTED FROM 1-OCTEN-3-OL, 3-OCTANOL, 3-METHYLBUTANOL; EFFECTIVE TRAP FOR OKRYZAEPHILUS SURINAMENSIS BETTLE | THE MINISTER OF AGRICULTURE FISHERIES AND FOOD IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE U.K. OF GT. BRITAIN AND N. IRELAND (GB) | 1997-08-12 | — | — | US | disclosed |
| EP-0338887-B1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMA (US) | 1993-12-08 | — | — | EP | disclosed |
| US-4988680-A | Phosphorylase inhibitors, immuno suppressants, parasiticides, antileukemia agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0228222-B1 | PESTICIDAL DIHALOVINYLALKENYLAMIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-05-23 | — | — | EP | disclosed |
| CN-1037342-A | Phosphonoalkylpurinederivatives derivatives | MERRELL DOW PHARMA (US) | 1989-11-22 | — | — | CN | disclosed |
| EP-0338887-A1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| EP-0338168-A1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| EP-0228222-A2 | Pesticidal dihalovinylalkenylamides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423914-A1 | AMIDE CONTAINING LIPIDS | PHOSPHO1, SGMS1, SGMS2 | L3MBTL1 178/4885TDP1 2503/4885TSHR 1040/4885 |
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | SNRPA, F12, ABCB4 | L3MBTL1 480/4885TDP1 1615/4885TSHR 1525/4885 |
| US-20040253177-A1 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | FABP1, FABP3, FFAR2 | L3MBTL1 1346/4885TDP1 3902/4885TSHR 793/4885 |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | L3MBTL1 295/4885TDP1 1579/4885TSHR 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.